KMT2B

Across TCGA pan-cancer cohorts, KMT2B mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated KMT2B data layer compared with 27 for mass-spec protein and 11 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher KMT2B mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated KMT2B expression acts as an unfavorable survival marker, although some lineages such as CCRCC and HNSC show a favorable association.

CCRCC, HNSC, and PDAC are the cancer types where KMT2B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	1.000	0.531	.006	13	view →
HNSC	OS	Tertile	II,III,IV	1.000	0.921	.009	13	view →
PDAC	OS	Quartile	All	0.175	0.515	.010	12	view →
GBM	OS	Quartile	All	0.718	0.374	.006	7	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

KMT2B–CCRCC (DFS)

Open the CCRCC breakdown →